Dynasil Cp America (DYSL) 1.44 $DYSL
Dynasil Corporation of America Reports Continued Revenue Growth in its Optics Business for Fiscal 2016's Second Quarter at 23%
PR Newswire - Thu May 12, 1:00PM CDT
Dynasil Corporation of America (NASDAQ: DYSL), a developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets, today announced a strong revenue showing by its Optics segment. The Optics companies reported revenues of $6.4 million in the quarter ended March 31, 2016 compared to $5.2 million of revenues in the same period of 2015. This $1.2 million increase represents a 23% increase in Optics segment revenue year over year. Certain key metrics by segment for the current quarter and the same quarter last year are presented below:
DYSL: 1.44 (+0.02)
Dynasil's RMD Subsidiary Awarded $3.8 Million in Technology Development Grants by NASA, National Institute of Health and Department of Energy
PR Newswire - Tue May 10, 12:00PM CDT
Dynasil Corporation of America (NASDAQ: DYSL) today announced that its contract research subsidiary, RMD Inc., has received six grants totaling $3.8 million under the NASA, National Institute of Health and Department of Energy's funding programs.
DYSL: 1.44 (+0.02)
Dynasil Corporation Schedules Fiscal 2016 Second Quarter Financial Results Conference Call
PR Newswire - Thu May 05, 12:00PM CDT
Dynasil Corporation of America (NASDAQ: DYSL) plans to release financial results for the quarter ended March 31, 2016 on Thursday, May 12 and management will host a conference call for investors and analysts that day at 5:00 p.m. ET.
DYSL: 1.44 (+0.02)
Dynasil Corporation Schedules First Quarter Fiscal 2016 Financial Results Conference Call
PR Newswire - Fri Feb 05, 10:15AM CST
Dynasil Corporation of America (NASDAQ: DYSL) plans to release financial results for the quarter ended December 31, 2015 on Thursday, February 11 and management will host a conference call for investors and analysts that day at 5:00 p.m. ET.
DYSL: 1.44 (+0.02)
Xcede Technologies Announces Collaboration with Cook Biotech Inc.
PR Newswire - Wed Jan 06, 2:05PM CST
Xcede Technologies, Inc. today announced that it has signed three collaboration agreements with Cook Biotech Inc. of West Lafayette, IN including a Development Agreement, a License Agreement and a Supply Agreement to complete development, seek regulatory clearance and produce Xcede's resorbable hemostatic patch.
DYSL: 1.44 (+0.02)
Dynasil Corporation Schedules Fiscal 2015 Financial Results Conference Call
PR Newswire - Thu Dec 10, 8:15AM CST
Dynasil Corporation of America (NASDAQ: DYSL) plans to release financial results for the fiscal year ended September 30, 2015 on Thursday, December 17 and management will host a conference call for investors and analysts that day at 5:00 p.m. ET.
DYSL: 1.44 (+0.02)
Dynasil Appoints Gary J. Bishop EVP - Photonics
PR Newswire - Tue Dec 01, 9:00AM CST
Dynasil Corporation of America ("Dynasil" or the "Company"
(NASDAQ: DYSL), a developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets, today announced the appointment of Gary J. Bishop, Ph.D., to the newly created position of EVP - Photonics.
DYSL: 1.44 (+0.02)
Dynasil Announces Retirement of CFO Thomas Leonard; Corporate Controller Robert Bowdring Named as Successor
PR Newswire - Fri Nov 13, 3:01PM CST
Dynasil Corporation of America ("Dynasil" or the "Company" (NASDAQ: DYSL), a developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets, today announced the planned succession of the Company's senior financial leadership.
DYSL: 1.44 (+0.02)
Dynasil Moves to Reduce Credit Cost
PR Newswire - Wed Oct 07, 3:10PM CDT
Dynasil Corporation of America ("Dynasil" or the "Company" (NASDAQ: DYSL), a developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets, announced today that it made $2 million of optional prepayments on its $3 million principal amount of subordinated debt with Massachusetts Capital Resource Company ("MCRC" . In connection with the prepayment, MCRC agreed to reduce the interest rate from ten percent to six percent per year, as well as extend the term of the remaining debt one year to July 31, 2018.
DYSL: 1.44 (+0.02)
BUYINS.NET: DYSL SqueezeTrigger Price is $2.01. There is $90,720 That Short Sellers Still Need To Cover.
M2 - Thu Sep 24, 3:22AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Dynasil Corp of America (NASDAQ
YSL) in real time and just received an alert that DYSL is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 43200 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $2.01. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
DYSL: 1.44 (+0.02)
Dynasil Announces Linda Zuckerman, Ph.D. as New CEO of Xcede Technologies, Inc.
PR Newswire - Tue Sep 15, 8:15AM CDT
Dynasil Corporation of America (NASDAQ: DYSL) today announced the appointment of Linda Zuckerman, Ph.D. as CEO of Xcede Technologies, Inc., Dynasil's majority owned subsidiary.
DYSL: 1.44 (+0.02)
Dynasil's Hilger Crystals Subsidiary Enters into Supply Arrangement
PR Newswire - Thu Aug 20, 8:00AM CDT
Dynasil Corporation of America (NASDAQ: DYSL) today announced that Dynasil's UK subsidiary, Hilger Crystals, Ltd., entered into a three year arrangement to supply high-quality crystal components to a leading global supplier of security inspection equipment utilizing X-ray and gamma-ray imaging.
DYSL: 1.44 (+0.02)
Dynasil Announces Xcede Technologies' Patent Application for Novel All-in-One Patch
PR Newswire - Tue Aug 18, 2:40PM CDT
Dynasil Corporation of America (NASDAQ: DYSL) today announced the conversion of Xcede Technologies, Inc.'s provisional U.S. Patent application claiming novel tissue patch systems, methods and compositions.
DYSL: 1.44 (+0.02)
Dynasil Corporation of America Reports Third Quarter Fiscal 2015 Financial Results
PR Newswire - Wed Aug 12, 3:01PM CDT
Dynasil Corporation of America (NASDAQ: DYSL), a developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets, today announced financial results for the fiscal 2015 third quarter ended June 30, 2015.
DYSL: 1.44 (+0.02)
Dynasil Corporation of America Reports Second Quarter Fiscal 2015 Financial Results
PR Newswire - Wed May 13, 3:01PM CDT
Dynasil Corporation of America (NASDAQ: DYSL), a developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets, today announced financial results for the fiscal 2015 second quarter ended March 31, 2015.
DYSL: 1.44 (+0.02)
100 M&A Focused Medical Devices/Technology/Supplies Companies 2015
M2 - Wed Apr 15, 8:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7d4bk7/manda_focused) has announced the addition of the "M&A Focused Medical Devices/Technology/Supplies 100 - An Industry Report" report to their offering. This report newly launched report identifies 100 M&A Focused medical devices/technology/supplies companies and covers various aspects of these 100 companies including news, financial/non-financial information, and stock market analysis. Alliances and partnerships have traditionally been used to help companies reduce their funding and resource burden and provide potential upside. These non-dilutive sources of funding can take many forms and warrant a second look in the light of today's difficult economy. A panel of seasoned medical device executives will analyze several recent partnering deals and contemplate their usefulness as alternative funding sources. Practical take-away include: how to integrate product co-development into your innovation strategy, understanding the key differences in structuring partnership deals with large and small companies and universities and/or research centers, understanding the pitfalls, risks and opportunities that these partnering models present, and understanding how to leverage these relationships to create win-win scenarios to the benefit all participants. M&A environment in 2015 is anticipated to continue its strong growth trends. Strategic and private equity acquisition appetites for strong healthcare companies continue to grow and this offers tremendous liquidity opportunities for business owners. As strategic acquirers become increasingly aggressive in their pursuit of new sources of growth, the robust capital markets welcome the next wave of growth companies. Despite significant challenges in reimbursement and other operating factors, many healthcare providers continue to grow profitably by scaling their businesses. While this growth comes at a significant cost to gross margins, we see efficient companies continuing to generate strong overall profits and hence, attractive acquisition opportunities. Report Highlights: - M&A Focused 100 medical devices/technology/supplies companies - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of M&A Focused medical devices/technology/supplies companies with foreign companies - International presence of M&A Focused medical devices/technology/supplies companies - Key R&D activities by M&A Focused medical devices/technology/supplies companies Key Topics Covered: 1: Rankings of M&A Focused Medical Devices/Technology/Supplies Companies 2: Stock Market Performance over 5 Years: Leading 25 M&A Focused Medical Devices/Technology/Supplies Companies 3: Key News of M&A Focused Medical Devices/Technology/Supplies Companies for Year 2014 4: Important Alliances of M&A Focused Medical Devices/Technology/Supplies Companies with Foreign Companies 5: Research and Development Activities by M&A Focused Medical Devices/Technology/Supplies Companies 6: International Presence of M&A Focused Medical Devices/Technology/Supplies Companies 7: Mergers and Acquisitions of M&A Focused Medical Devices/Technology/Supplies Companies Companies Mentioned Sample list of company names included in this industry report: - 3M Company (United States) - Abaxis Inc (United States) - Abcam Plc (United Kingdom) - Advanced Oncotherapy PLC (United Kingdom) - Aerocrine Ab (Sweden) - Alfresa Pharma Corp (Japan) - Andon Health Company Limited (China) - Angiodynamics, Inc. (United States) - Anteo Diagnostics Limited (Australia) - Atcor Medical Holdings Ltd (Australia) - Azure Healthcare Ltd. (Australia) - Bio Rad Laboratories Incorporated (United States) - Bruker Corporation (United States) - Capitol Health Ltd (Australia) - Carefusion Corporation (United States) - Carl Zeiss Co., Ltd. (Japan) - Cellectis SA (France) - Coherent Incorporated (United States) - Cooper Companies Inc. (United States) - Corgenix Medical Corporation (United States) - Dynasil Corporation Of America (United States) - Heartware International Inc (Australia) - Hill-Rom Holdings, Incorporation (United States) - Jeol Limited (Japan) - Paragon Care Limited (Australia) - Smith & Nephew PLC (United Kingdom) - Tecan Group AG (Switzerland) - Veracyte, Inc. (United States) - Vitrolife AB (Sweden) - Volcano Corporation (United States) For more information visit http://www.researchandmarkets.com/research/7d...da_focused
MMM: 178.15 (-0.14), COO: 182.61 (+0.14), SNN: 33.53 (+0.35), VCYT: 4.98 (+0.03), ABAX: 49.14 (-0.32), DYSL: 1.44 (+0.02), VOLC: 17.99 (+0.01), CLLS: 26.91 (-0.19), COHR: 107.10 (+1.05), HRC: 54.02 (+0.59)
Dynasil Corporation of America Reports Continued Revenue Growth in its Optics Business for Fiscal 2016's Second Quarter at 23%
PR Newswire - Thu May 12, 1:00PM CDT
Dynasil Corporation of America (NASDAQ: DYSL), a developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets, today announced a strong revenue showing by its Optics segment. The Optics companies reported revenues of $6.4 million in the quarter ended March 31, 2016 compared to $5.2 million of revenues in the same period of 2015. This $1.2 million increase represents a 23% increase in Optics segment revenue year over year. Certain key metrics by segment for the current quarter and the same quarter last year are presented below:
DYSL: 1.44 (+0.02)
Dynasil's RMD Subsidiary Awarded $3.8 Million in Technology Development Grants by NASA, National Institute of Health and Department of Energy
PR Newswire - Tue May 10, 12:00PM CDT
Dynasil Corporation of America (NASDAQ: DYSL) today announced that its contract research subsidiary, RMD Inc., has received six grants totaling $3.8 million under the NASA, National Institute of Health and Department of Energy's funding programs.
DYSL: 1.44 (+0.02)
Dynasil Corporation Schedules Fiscal 2016 Second Quarter Financial Results Conference Call
PR Newswire - Thu May 05, 12:00PM CDT
Dynasil Corporation of America (NASDAQ: DYSL) plans to release financial results for the quarter ended March 31, 2016 on Thursday, May 12 and management will host a conference call for investors and analysts that day at 5:00 p.m. ET.
DYSL: 1.44 (+0.02)
Dynasil Corporation Schedules First Quarter Fiscal 2016 Financial Results Conference Call
PR Newswire - Fri Feb 05, 10:15AM CST
Dynasil Corporation of America (NASDAQ: DYSL) plans to release financial results for the quarter ended December 31, 2015 on Thursday, February 11 and management will host a conference call for investors and analysts that day at 5:00 p.m. ET.
DYSL: 1.44 (+0.02)
Xcede Technologies Announces Collaboration with Cook Biotech Inc.
PR Newswire - Wed Jan 06, 2:05PM CST
Xcede Technologies, Inc. today announced that it has signed three collaboration agreements with Cook Biotech Inc. of West Lafayette, IN including a Development Agreement, a License Agreement and a Supply Agreement to complete development, seek regulatory clearance and produce Xcede's resorbable hemostatic patch.
DYSL: 1.44 (+0.02)
Dynasil Corporation Schedules Fiscal 2015 Financial Results Conference Call
PR Newswire - Thu Dec 10, 8:15AM CST
Dynasil Corporation of America (NASDAQ: DYSL) plans to release financial results for the fiscal year ended September 30, 2015 on Thursday, December 17 and management will host a conference call for investors and analysts that day at 5:00 p.m. ET.
DYSL: 1.44 (+0.02)
Dynasil Appoints Gary J. Bishop EVP - Photonics
PR Newswire - Tue Dec 01, 9:00AM CST
Dynasil Corporation of America ("Dynasil" or the "Company"
(NASDAQ: DYSL), a developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets, today announced the appointment of Gary J. Bishop, Ph.D., to the newly created position of EVP - Photonics. DYSL: 1.44 (+0.02)
Dynasil Announces Retirement of CFO Thomas Leonard; Corporate Controller Robert Bowdring Named as Successor
PR Newswire - Fri Nov 13, 3:01PM CST
Dynasil Corporation of America ("Dynasil" or the "Company"
(NASDAQ: DYSL), a developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets, today announced the planned succession of the Company's senior financial leadership. DYSL: 1.44 (+0.02)
Dynasil Moves to Reduce Credit Cost
PR Newswire - Wed Oct 07, 3:10PM CDT
Dynasil Corporation of America ("Dynasil" or the "Company"
(NASDAQ: DYSL), a developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets, announced today that it made $2 million of optional prepayments on its $3 million principal amount of subordinated debt with Massachusetts Capital Resource Company ("MCRC" . In connection with the prepayment, MCRC agreed to reduce the interest rate from ten percent to six percent per year, as well as extend the term of the remaining debt one year to July 31, 2018. DYSL: 1.44 (+0.02)
BUYINS.NET: DYSL SqueezeTrigger Price is $2.01. There is $90,720 That Short Sellers Still Need To Cover.
M2 - Thu Sep 24, 3:22AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Dynasil Corp of America (NASDAQ
YSL) in real time and just received an alert that DYSL is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 43200 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $2.01. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com . DYSL: 1.44 (+0.02)
Dynasil Announces Linda Zuckerman, Ph.D. as New CEO of Xcede Technologies, Inc.
PR Newswire - Tue Sep 15, 8:15AM CDT
Dynasil Corporation of America (NASDAQ: DYSL) today announced the appointment of Linda Zuckerman, Ph.D. as CEO of Xcede Technologies, Inc., Dynasil's majority owned subsidiary.
DYSL: 1.44 (+0.02)
Dynasil's Hilger Crystals Subsidiary Enters into Supply Arrangement
PR Newswire - Thu Aug 20, 8:00AM CDT
Dynasil Corporation of America (NASDAQ: DYSL) today announced that Dynasil's UK subsidiary, Hilger Crystals, Ltd., entered into a three year arrangement to supply high-quality crystal components to a leading global supplier of security inspection equipment utilizing X-ray and gamma-ray imaging.
DYSL: 1.44 (+0.02)
Dynasil Announces Xcede Technologies' Patent Application for Novel All-in-One Patch
PR Newswire - Tue Aug 18, 2:40PM CDT
Dynasil Corporation of America (NASDAQ: DYSL) today announced the conversion of Xcede Technologies, Inc.'s provisional U.S. Patent application claiming novel tissue patch systems, methods and compositions.
DYSL: 1.44 (+0.02)
Dynasil Corporation of America Reports Third Quarter Fiscal 2015 Financial Results
PR Newswire - Wed Aug 12, 3:01PM CDT
Dynasil Corporation of America (NASDAQ: DYSL), a developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets, today announced financial results for the fiscal 2015 third quarter ended June 30, 2015.
DYSL: 1.44 (+0.02)
Dynasil Corporation of America Reports Second Quarter Fiscal 2015 Financial Results
PR Newswire - Wed May 13, 3:01PM CDT
Dynasil Corporation of America (NASDAQ: DYSL), a developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets, today announced financial results for the fiscal 2015 second quarter ended March 31, 2015.
DYSL: 1.44 (+0.02)
100 M&A Focused Medical Devices/Technology/Supplies Companies 2015
M2 - Wed Apr 15, 8:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7d4bk7/manda_focused) has announced the addition of the "M&A Focused Medical Devices/Technology/Supplies 100 - An Industry Report" report to their offering. This report newly launched report identifies 100 M&A Focused medical devices/technology/supplies companies and covers various aspects of these 100 companies including news, financial/non-financial information, and stock market analysis. Alliances and partnerships have traditionally been used to help companies reduce their funding and resource burden and provide potential upside. These non-dilutive sources of funding can take many forms and warrant a second look in the light of today's difficult economy. A panel of seasoned medical device executives will analyze several recent partnering deals and contemplate their usefulness as alternative funding sources. Practical take-away include: how to integrate product co-development into your innovation strategy, understanding the key differences in structuring partnership deals with large and small companies and universities and/or research centers, understanding the pitfalls, risks and opportunities that these partnering models present, and understanding how to leverage these relationships to create win-win scenarios to the benefit all participants. M&A environment in 2015 is anticipated to continue its strong growth trends. Strategic and private equity acquisition appetites for strong healthcare companies continue to grow and this offers tremendous liquidity opportunities for business owners. As strategic acquirers become increasingly aggressive in their pursuit of new sources of growth, the robust capital markets welcome the next wave of growth companies. Despite significant challenges in reimbursement and other operating factors, many healthcare providers continue to grow profitably by scaling their businesses. While this growth comes at a significant cost to gross margins, we see efficient companies continuing to generate strong overall profits and hence, attractive acquisition opportunities. Report Highlights: - M&A Focused 100 medical devices/technology/supplies companies - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of M&A Focused medical devices/technology/supplies companies with foreign companies - International presence of M&A Focused medical devices/technology/supplies companies - Key R&D activities by M&A Focused medical devices/technology/supplies companies Key Topics Covered: 1: Rankings of M&A Focused Medical Devices/Technology/Supplies Companies 2: Stock Market Performance over 5 Years: Leading 25 M&A Focused Medical Devices/Technology/Supplies Companies 3: Key News of M&A Focused Medical Devices/Technology/Supplies Companies for Year 2014 4: Important Alliances of M&A Focused Medical Devices/Technology/Supplies Companies with Foreign Companies 5: Research and Development Activities by M&A Focused Medical Devices/Technology/Supplies Companies 6: International Presence of M&A Focused Medical Devices/Technology/Supplies Companies 7: Mergers and Acquisitions of M&A Focused Medical Devices/Technology/Supplies Companies Companies Mentioned Sample list of company names included in this industry report: - 3M Company (United States) - Abaxis Inc (United States) - Abcam Plc (United Kingdom) - Advanced Oncotherapy PLC (United Kingdom) - Aerocrine Ab (Sweden) - Alfresa Pharma Corp (Japan) - Andon Health Company Limited (China) - Angiodynamics, Inc. (United States) - Anteo Diagnostics Limited (Australia) - Atcor Medical Holdings Ltd (Australia) - Azure Healthcare Ltd. (Australia) - Bio Rad Laboratories Incorporated (United States) - Bruker Corporation (United States) - Capitol Health Ltd (Australia) - Carefusion Corporation (United States) - Carl Zeiss Co., Ltd. (Japan) - Cellectis SA (France) - Coherent Incorporated (United States) - Cooper Companies Inc. (United States) - Corgenix Medical Corporation (United States) - Dynasil Corporation Of America (United States) - Heartware International Inc (Australia) - Hill-Rom Holdings, Incorporation (United States) - Jeol Limited (Japan) - Paragon Care Limited (Australia) - Smith & Nephew PLC (United Kingdom) - Tecan Group AG (Switzerland) - Veracyte, Inc. (United States) - Vitrolife AB (Sweden) - Volcano Corporation (United States) For more information visit http://www.researchandmarkets.com/research/7d...da_focused
MMM: 178.15 (-0.14), COO: 182.61 (+0.14), SNN: 33.53 (+0.35), VCYT: 4.98 (+0.03), ABAX: 49.14 (-0.32), DYSL: 1.44 (+0.02), VOLC: 17.99 (+0.01), CLLS: 26.91 (-0.19), COHR: 107.10 (+1.05), HRC: 54.02 (+0.59)
